期刊文献+

系统性红斑狼疮合并巨细胞病毒感染121例临床分析 被引量:5

Cytomegalovirus infection in systemic lupus erythematosus: an analysis of 121 cases
原文传递
导出
摘要 目的探讨系统性红斑狼疮(SLE)合并巨细胞病毒(CMV)感染的临床表现。方法分析SLE合并CMV感染患者的相关临床资料,进行统计分析。结果2221例SLE住院患者中,合并CMV活动性感染121例,发生率为5.4%。发热98例占81%,其中80例(66.1%)以发热为唯一表现,肝功能损害8例、呼吸道症状5例、血液系统异常4例、心肌炎和脑病各1例,分别占6.6%、4.1%、3.3%、0.8%、0.8%;另22例(18.2%)不明原因原发病活动而经检查发现CMV感染。75.2%患者SLE疾病活动指数达10分以上。121例中,4例死亡,6例放弃治疗。其余患者CMV感染均于治疗2.4周[(15±6)d]得到控制。结论CMV感染是SLE的常见合并症,临床表现无特征性,对不明原因发热者应及时做CMV的相关检查以利诊断。 Objective To investigate the clinical manifestations of cytomegalovirus (CMV) infection in patients with systemic lupus erythematosus (SLE). Methods Data of the consecutive cases of SLE complicated with active CMV infection including clinical manifestations, SLEDAI score, dosage of corticosteroid and immunosuppressants used for treatment, radiological and laboratory examinations were collected and analyzed. Results Among 2221 consecutive patients of SLE, 5.4%(121 cases) were diagnosed to be complicated with active CMV infection. Fever was the most common symptom, followed by serious liver function damage, respiratory symptoms, hematological abnormalities, myocarditis, and encephalopathy, accounted for 8 t % (98 cases), 6.6%(8 cases), 4.1%(5 cases), 3.3%(4 cases), 0.8%(1 case), and 0.8%(1 case)respectively; in addition, 22 (18.2%) cases had no symptom. SLEDAI was higher than 15 in 47.1% cases, and 10-14 in 28.1% cases. 81% of patients were treated with corticosteroid, and 55.4% were treated with immunosuppressants. Ganciclovir was given once the diagnosis of active CMV infection was established. In most of the patients, active CMV infection had been controlled within 14-28 days, except 4 died and 6 gave up the therapy. Conclusion SLE with active CMV infection is common, especially in patients who are treated with corticosteroid and/or immunosuppressants. Clinical manifestations of SLE complicated with active CMV infection are generally nonspecific. In patients with unexplained fever, or liver damage, or lung disease, or active SLE patients who have no symptom but are refractory to the treatment, CMV infection should be suspected and the relevant laboratory, tests should be ordered for early diagnosis and treatment.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2011年第4期249-251,共3页 Chinese Journal of Rheumatology
关键词 红斑狼疮 系统性 巨细胞病毒感染 糖皮质激素 Lupus erythematosus, systemic Cytomegalovirus infection Corticosteroid
  • 相关文献

参考文献12

  • 1Bosch X, Guilabert A, Pallares L, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110patients. Lupus, 2006, 15: 584-589.
  • 2Funk G, Gosert R, Hitch H. Viral dynamics in trasplant pa- tients: implications for disease. Lancet Infect Dis, 2007, 7: 460-472.
  • 3郝英英,许慧,崔京涛,倪安平.SLE患者血清急性巨细胞病毒pp65的抗原及IgM类抗体检测[J].临床检验杂志,2006,24(3):190-190. 被引量:2
  • 4Tang W, Ehnore SH, Fan H, et al. Cytomegalovirus DNA mea-surement in blood and plasma using Roche LightCycler CMV quantification reagents. Diagn Mol Pathol, 2005, 17: 166-173.
  • 5Barzilai O, Sherer Y, Ram M, et al. Epstein-Barr virus and ey- tomegalovirus in autoimmune diseases: are they truly notorious? Apreliminary report. Ann NY Acad Sci, 2007, 1108: 567-577.
  • 6Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis, 2002, 34: 1094-1097.
  • 7Sekigawa I, Nawata M, Seta N, et al. Cytomegalovirus infection in patient with systemic lupus erythematosus. Clin Exp Rheuma-tol, 2002, 20: 559-564.
  • 8Takizawa Y, lnokuma S, Tanaka Y. Clinical characteristics of cytomegalovirus infection in rheumatic disease: multicentre sur-vey in a large patient population. Rheumatology (Oxford), 2008, 47: 1373-1378.
  • 9王焕玲,邱志峰,盛瑞媛,赵岩,朱晓春,郝英英,范洪伟,吕玮,马小军,刘正印,李太生.巨细胞病毒病50例临床分析[J].中华内科杂志,2004,43(8):600-603. 被引量:21
  • 10崔寰,陈伟,夏俊保,刘倩,黄维,李迎伟,王明丽.人巨细胞病毒感染与系统性红斑狼疮病情活动性的关联性研究[J].安徽医科大学学报,2008,43(5):508-511. 被引量:8

二级参考文献26

  • 1赵缜,孙洪斌,彭奕冰,季育华.检测pp65抗原和IgM抗体对移植患者CMV活动性感染监测价值比较[J].临床检验杂志,2004,22(4):278-279. 被引量:12
  • 2Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? [J]. Intern Med,2006,259(3) :219 -46.
  • 3Segal B H, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases [ J ]. Rheum Dis Clin North Am, 1997, 23(2) :219 -37.
  • 4Lefkowith J B, Gilkeson G S. Nephritogenic antoantibodies in lupus:current concepts and continuing controversies [ J ]. Athritis Rheum, 1996,39(6) :894 -903.
  • 5Klein-Gitelman M. Pediatric lupus versus adult lupus role of the laboratory [ J ]. Clin Applied Immunol Rev, 2004,4 ( 5 ) : 333 - 50.
  • 6Chang M, Pan M R, Chen D Y, et al. Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice[ J]. Clin Exp Immunol,2006,143 ( 1 ) : 167 - 79.
  • 7Sekigawa I, Nawata M, Seta N, et al. Cytomegalovirus infection in patients with systemic lupus erythematosus[ J ]. Clin Exp Rheumatol , 2002,20 ( 4 ) : 559 - 64.
  • 8Barzilai O, Sharer Y, Ram M, et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report[J]. Ann N Y Acad Sci,2007,1108:567 -77.
  • 9Hochberg M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [ J ]. Arthritis Rheum, 1997,40 ( 9 ) : 1725.
  • 10Bombardier C, Gladmann D D, Urowitz M B, et al. Committee on prognosis studies in SLE. Derivation of the SLEDAI: a diease activity index for lupus patients [ J ]. Arthritis Rheum , 1992,35 (6) : 630 - 40.

共引文献26

同被引文献59

引证文献5

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部